One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment.
Researchers have identified a genomic variant strongly associated with sensitivity to the sun, brown hair, blue eyes - and freckles. In the study of Icelanders the researchers uncovered an intricate pathway involving the interspersed DNA sequence, or non-coding region, of a gene that is among a few dozen that are associated with human pigmentation traits.
Melanoma is the deadliest form of skin cancer, killing more than 8,000 in the U.S. each year. Approximately 40 percent of advanced melanoma tumors are driven to grow by the presence of mutations in a gene known as the BRAF gene.
Although most of the melanomas that harbor BRAF mutations respond dramatically to treatment with BRAF inhibitors, nearly all develop resistance to the drugs in less than a year, and previous studies showed that melanomas alter a cell signaling pathway called the MAPK pathway to become resistant.
Genomic profiling of treatment-resistant, BRAF-mutated melanomas revealed multiple gene alterations, mostly involving a cell-signaling pathway called the MAPK pathway, and more potent forms of existing drugs and drugs targeting the protein ERK may provide durable control of the disease, according to two studies published in Cancer Discovery, a journal of the […]
Aurora-A is a protein involved in the cell division process that is highly expressed or synthesised in a large number of human cancers, especially in those associated with a bad prognosis. Several pharmaceutical companies have recently developed these protein inhibitors, although the therapeutic and physiological effects that blocking Aurora-A might have on […]
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional data for MK-3475, an investigational anti-PD-1 immunotherapy, in patients with advanced melanoma that showed an estimated overall survival rate of 81 percent at one year across all MK-3475 monotherapy doses evaluated.
The layers of skin that form the first line of defence in the body's fight against infection have revealed a unanticipated secret.The single cell type that was thought to be behind the skin's immune defence has been found to have a doppelganger, with researchers from the Walter and Eliza Hall Institute showing the cells, despite appearing identical […]
Researchers from IMIM (Hospital del Mar Medical Research Institute) lead by Dr. Sandra Peiró have described a new function for two key molecules involved in tumor progression. Transcription factor SNAIL1 and enzyme LOXL2 are essential to Epithelial-Mesenchymal Transition (EMT); meaning the process by which tumor cells are able to move and reach other tissues […]
Primary care physicians who took an online training course about skin cancer detection significantly improved their skill to properly diagnose and manage benign and malignant lesions, according to a national study from Henry Ford Hospital in Detroit.The physicians' enhanced skill level also led to a reduction in unnecessary referrals to dermatology spec […]